ModerateVitamin K antagonist anticoagulants×Fluoroquinolone antibacterials
Updated · Methodology
Mechanism
In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ciprofloxacin inhibits CYP1A2, and the Spanish SmPC calls it a moderate inhibitor of this enzyme (ciprofloxacin SmPC, AEMPS; ciprofloxacin prescribing information, US Food and Drug Administration, FDA). The Spanish SmPC states that ciprofloxacin can potentiate vitamin K antagonists and names acenocoumarol explicitly among them. The contribution of ciprofloxacin itself to a rise in the international normalised ratio (INR) cannot be determined precisely, because the risk depends on the infection, age and general condition of the patient (AEMPS; FDA). The documents do not say whether the INR rise is linked to CYP1A2 inhibition. The acenocoumarol SmPCs list fluoroquinolones, and the generic SmPC names ciprofloxacin explicitly, among the drugs that can potentiate acenocoumarol (acenocoumarol SmPCs, AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. According to the Spanish ciprofloxacin summary of product characteristics (SmPC), ciprofloxacin can potentiate acenocoumarol and other vitamin K antagonists and raise the international normalised ratio (INR). Post-marketing reports include both prolongation and shortening of the prothrombin time (ciprofloxacin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; ciprofloxacin prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. The Spanish ciprofloxacin SmPC names acenocoumarol and advises frequent checks of the international normalised ratio (INR) during and just after co-administration (ciprofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label advises caution with oral anticoagulants and frequent checks of the prothrombin time and INR during and shortly after co-administration (ciprofloxacin prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a ciprofloxacin course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Cipro (ciprofloxacin) prescribing information (2026)– FDA, DailyMed setid 888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0 (Bayer HealthCare), version 32, revised 03/2026, Boxed Warning, sections 5.1, 5.2, 5.12, 7 and 8.5
- AEMPS: Ficha técnica: Ciprofloxacino (nº registro 62765), sección 4.5 (2025)– AEMPS, CIMA, nº registro 62765, revisión 11/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9